Voriconazole camphorsulfonate
Based on 11 publication(s) in Google Scholar
Voriconazole (UK-109496) camphorsulfonate is a second-generation, broad-spectrum triazole antifungal agent that inhibits fungal ergosterol biosynthesis. Voriconazole camphorsulfonate exerts its antifungal activity by inhibition of 14-α-lanosterol demethylation, which is mediated by fungal cytochrome P450 enzymes.
For research use only. We do not sell to patients.
- CAS No.: 137234-71-0
- Formula: C26H30F3N5O5S
- Molecular Weight:581.61
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Voriconazole camphorsulfonate
More- Transl Res. 2022 Sep:247:39-57. [Abstract]
- Front Cell Infect Microbiol. 2020 Jun 26:10:320. [Abstract]
- BMC Microbiol. 2025 Nov 5;25(1):715. [Abstract]
- Microchem J. 2026 Mar 27.
- Microbiol Spectr. 2025 May 6;13(5):e0318524. [Abstract]
- Drug Metab Dispos. 2025 Nov;53(11):100168. [Abstract]
- Med Mycol. 2018 Jun 1;56(4):452-457. [Abstract]
- Infect Drug Resist. 2022 Dec 15:15:7459-7473. [Abstract]
- J Mycol Med. 2022 Mar;32(1):101227. [Abstract]
- Laryngoscope Investig Otolaryngol. 2022 Oct 28;7(6):1780-1789. [Abstract]
- bioRxiv. 2025 Oct 14:2025.10.13.682145. [Abstract]
Customer Validation & Images
-
Microbiological Assay
-
Microbiological Assay
-
Others
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
Biological Activity
Voriconazole camphorsulfonate has great activity against S. apiospermum and C. neoformans with the MICs of 0.5 μg/mL and 0.125–0.25 μg/mL, respectively[1].
Voriconazole camphorsulfonate inhibits the cytochrome P450 (CYP)-dependent enzyme 14-alpha-sterol demethylase, thereby disrupting the cell membrane and halting fungal growth[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male specific-pathogen-free BALB/cByJ mice[3]
-
Dosage:1, 5, 20 mg/kg/day
-
Administration:P.o. once daily for 21 days
-
Result:Improved survival in a dose-response fashion, with median survival times (MSTs) of 21, 28, and 35 days with doses of 1, 5, and 20 mg/kg, respectively.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 137234-71-0
-
Molecular Weight 581.61
-
Formula C26H30F3N5O5S
-
SMILES
O[C@@]([C@@H](C)C1=NC=NC=C1F)(CN2N=CN=C2)C(C(F)=C3)=CC=C3F.O=S(C[C@](C4=O)(CC[C@H]5C4)C5(C)C)(O)=O
-
Synonyms
UK-109496 camphorsulfonate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Transl Res
A dual action small molecule enhances azoles and overcomes resistance through co-targeting Pdr5 and Vma1. [Abstract]2022 Sep:247:39-57. PMID: 35452875 -
Front Cell Infect Microbiol
Caenorhabditis elegans- Based Aspergillus fumigatus Infection Model for Evaluating Pathogenicity and Drug Efficacy. [Abstract]2020 Jun 26:10:320. PMID: 32670897
Voriconazole camphorsulfonate purchased from MedChemExpress. Usage Cited in: Front Cell Infect Microbiol. 2020 Jun 26:10:320. [Abstract]
Kaplan-Meier survival plots of C. elegans infected by KU80Δ in the presence of antifungal drugs. The glp-4(bn2); sek-1(km4) worms were pre-infected with KU80Δ for 8 h then transferred into liquid killing media containing different concentrations of Voriconazole (0-1.5 μg/mL).
Voriconazole camphorsulfonate purchased from MedChemExpress. Usage Cited in: Front Cell Infect Microbiol. 2020 Jun 26:10:320. [Abstract]
Effect of antifungal treatment on Af293-dsRed infection to glp-4(bn2); sek-1(km4) worms. Images were taken under DIC and TRITC channels from DMSO treatment by 24 h, 1.5 μg/ml AmB treatment by 48 h, 2 μg/ml ItrZ treatment by 72 h and 0.5 μg/ml Voriconazole treatment by 72 h. Scale bar is 200 μm.
-
BMC Microbiol
In vitro combination effects and mechanisms of Revaprazan with Triazole antifungal drugs on Aspergillus. [Abstract]2025 Nov 5;25(1):715. PMID: 41194018
Voriconazole camphorsulfonate purchased from MedChemExpress. Usage Cited in: BMC Microbiol. 2025 Nov 5;25(1):715. [Abstract]
Interaction profile of REV combined with ITR, Voriconazole and POS against Aspergillus spp.
-
-
Microbiol Spectr
Synergistic antifungal activity of minocycline as an effective augmenting agent of fluconazole against drug-resistant Candida tropicalis. [Abstract]2025 May 6;13(5):e0318524. PMID: 40162832
Voriconazole camphorsulfonate purchased from MedChemExpress. Usage Cited in: Microbiol Spectr. 2025 May 6;13(5):e0318524. [Abstract]
MIC values of antifungal drugs (Voriconazole) against CT27.
-
Drug Metab Dispos
Metabolic flux analysis of bile acid biosynthesis acidic pathway in HepG2 cells reveals CYP8B1 inhibition of azole antifungals. [Abstract]2025 Nov;53(11):100168. PMID: 41124962 -
Med Mycol
2018 Jun 1;56(4):452-457. PMID: 29420769 -
Infect Drug Resist
Correlation Between Drug Resistance and Virulence of Candida Isolates from Patients with Candidiasis. [Abstract]2022 Dec 15:15:7459-7473. PMID: 36544991 -
J Mycol Med
In vitro synergistic effect of minocycline combined with antifungals against Cryptococcus neoformans. [Abstract]2022 Mar;32(1):101227. PMID: 34800920 -
Laryngoscope Investig Otolaryngol
Clinical and mycological investigations of post-COVID-19 acute invasive fungal sinusitis. [Abstract]2022 Oct 28;7(6):1780-1789. PMID: 36544940 -
bioRxiv
Cyp7b1-inhibiting azoles as novel enhancers of hematopoietic stem and progenitor cell mobilization. [Abstract]2025 Oct 14:2025.10.13.682145. PMID: 41279189
Voriconazole camphorsulfonate purchased from MedChemExpress. Usage Cited in: bioRxiv. 2025 Oct 14:2025.10.13.682145. [Abstract]
Experimental design for HSPC mobilization. Wild-type C57BL/6J or Townes SCD mice were treated with Voriconazole (50 mg/kg/day, iv) or vehicle intravenously daily for four days, followed by AMD3100 or vehicle one hour before peripheral blood collection for CFU assays.
Voriconazole camphorsulfonate purchased from MedChemExpress. Usage Cited in: bioRxiv. 2025 Oct 14:2025.10.13.682145. [Abstract]
Experimental design for HSPC mobilization. Wild-type C57BL/6J or Townes SCD mice were treated with Voriconazole (50 mg/kg/day, iv) or vehicle intravenously daily for four days, followed by AMD3100 or vehicle one hour before peripheral blood collection for CFU assays. Numbers of CFU-C in peripheral blood of C57BL/6J mice after the indicated treatments.
Voriconazole camphorsulfonate purchased from MedChemExpress. Usage Cited in: bioRxiv. 2025 Oct 14:2025.10.13.682145. [Abstract]
Experimental design for HSPC mobilization. Wild-type C57BL/6J or Townes SCD mice were treated withVvoriconazole (50 mg/kg/day, iv) or vehicle intravenously daily for four days, followed by AMD3100 or vehicle one hour before peripheral blood collection for CFU assays. Numbers of CFU-gmEM (C) in peripheral blood of C57BL/6J mice after the indicated treatments.
Purity & Documentation
References
[1]. Nickie D Greer. Voriconazole: the newest triazole antifungal agent.Proc (Bayl Univ Med Cent). 2003 Apr;16(2):241-8. [Content Brief]
[2]. Lesley J Scott, et al. Voriconazole : a review of its use in the management of invasive fungal infections.Drugs. 2007;67(2):269-98. [Content Brief]
[3]. A M Sugar,et al. Efficacy of voriconazole in treatment of murine pulmonary blastomycosis.Antimicrob Agents Chemother. 2001 Feb;45(2):601-4. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Voriconazole camphorsulfonate Related Classifications
HY-76200B Related Classifications
Powered by Bioz